Autopsy report · NCT01131247

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

“PI left institution”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Nevada Cancer Institute

Sponsor type

University, hospital or other

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

ofatumumab + bendamustine

Participants

37 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)
  “PI has left institution” (96% match in meaning)
• Cilostazol After Lower Extremity Arterial Revascularization Trial
  “Original PI left institution” (94% match in meaning)
• Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease
  “PI left the institution” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.